DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.
Transpl Infect Dis
; 15(1): E28-32, 2013 Feb.
Article
de En
| MEDLINE
| ID: mdl-23279859
ABSTRACT
Parainfluenza virus (PIV) may cause life-threatening pneumonia in lung transplant patients and there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase fusion protein, to treat severe PIV type 3 pneumonia in a lung transplant patient. Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Antiviraux
/
Infections à respirovirus
/
Pneumopathie virale
/
Protéines de fusion recombinantes
/
Transplantation pulmonaire
/
Virus parainfluenza humain de type 3
Type d'étude:
Etiology_studies
Limites:
Female
/
Humans
/
Middle aged
Langue:
En
Journal:
Transpl Infect Dis
Sujet du journal:
TRANSPLANTE
Année:
2013
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique